Lenalidomide for erdheim-chester disease

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Trial registered. A trial in people is registered. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 14 Aug 2015: Trial registered, NCT02523040

The trials

NCT02523040: Lenalidomide for Adult Histiocyte Disorders

State
Under way
Phase
Phase 2
People
12 taking part
Started
Aug 2015
Primary completion
Feb 2024
Arms
Lenalidomide
Results
Posted on the registry
  1. 14 Aug 2015: Trial registered
  2. 25 Apr 2025: Trial results posted

Posted results

The numbers the trial's sponsor posted to the registry, as written there. The registry record says what each measure runs from and to.

Overall Response Rate (ORR)

Primary outcome · Number, proportion of participants · Disease assessed every 3 cycles on treatment up do 12 cycles (approximately 12 months).

GroupAnalysedValue
Lenalidomide120.67 (90% Confidence Interval 0.39 to 0.88)

12-months Progression-free Survival (PFS)

Secondary outcome · Number, percentage probability · Disease assessed on treatment every 3 cycles and in long-term follow-up up to the earlier of 36 months (every 3 months for 2 years then every 6 months) or start of new anti-cancer therapy. Relevant for this endpoint was12-months estimate.

GroupAnalysedValue
Lenalidomide1262 (95% Confidence Interval 39 to 100)

12-months Overall Survival (OS)

Secondary outcome · Number, percentage probability · 12 Months

GroupAnalysedValue
Lenalidomide1292 (95% Confidence Interval 77 to 100)

Incidence of Grade 3-4 Toxicity

Secondary outcome · Number, proportion of participants · Up to 12 months on treatment.

GroupAnalysedValue
Lenalidomide120.25 (90% Confidence Interval 0.07 to 0.53)

Percent Change in Serum TNF-alpha Levels on Therapy From Baseline up to 12 Cycles

Secondary outcome · Median, percent change from baseline · Measured at baseline, day 1 of cycles 3, 6 ad 12 cycles and within 28 days post-treatment end (up to 13 months).

GroupAnalysedValue
Lenalidomide6-14.4 (Full Range -67.3 to 8.3)

How the status changed

  1. 19 Nov 2026: First set: Trial registered

About the treatment

Kind of treatment: Drug.

Also known as Revlimid.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.